

\$1633



RECEIVED

FEB 27 2002

TECH CENTER 1600/2900

PATENT
Docket No. 27373/36638A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4/K.T.
2/28
I.D.S.

Applicants: Weichselbaum, et al.
Serial No.: 09/964,042
Filed: September 26, 2001
For: Treatment of Tumors With
Genetically Engineered Herpes
Virus
Group Art Unit: 1633
Examiner: B. Puri

) I hereby certify that this paper and the
) papers referred to as attached are being
) deposited with the United States Postal
) Service, as first class mail, postage prepaid
) in an envelope addressed to the
) Commissioner of Patents, Washington,
) D.C. on February 5, 2002.

Joseph A. Williams, Jr.
(Reg. No. 38,659)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the attached PTO-1449 form is submitted by Applicants for consideration in connection with the above-identified patent application. Copies of all references can be found in corresponding U.S. Serial No. 09/244,748.

This statement and PTO-1449 form are submitted after receipt of a first Office Action in the above-identified patent application. Accordingly, it is submitted that a fee in the amount of \$180.00 is due in this matter under 37 C.F.R. §1.97(c). The Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees which may be required to Deposit Account No. 13-2855. A duplicate of this paper is enclosed.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

02/22/2002 VTRUONG1 00000116 132855 09964042 By
01 FC:126 180.00 CH

Joseph A. Williams, Jr. (Reg. No. 38,659)
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

February 5, 2002